Lenvatinib Mesylate

Category API

Details	Specifications
CAS Number	857890-39-2
Molecular Formula	C22H23ClN4O7S
Molecular Weight	522.96 g/mol.
Synonyms	4-[3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-quinolinecarboxamide mesylate
Chemical Name	4-[3-Chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide methane sulfonate
Common name	Lenvatinib Mesylate
Therapeutic use	Lenvatinib mesylate is an oral tyrosine kinase inhibitor used to treat advanced, treatment-resistant thyroid cancer, unrespectable liver cancer (HCC), and certain renal cell/endometrial carcinomas. It acts as an antiangiogenic agent, blocking vascular endothelial growth factor (VEGF) receptors to inhibit tumor blood supply.
Background	Lenvatinib mesylate is an oral, multi-kinase inhibitor for targeted cancer treatment. It works by inhibiting vascular endothelial growth factor receptors (VEGFR1–3), fibroblast growth factor receptors (FGFR1–4), and other kinases, inhibiting tumor growth and angiogenesis. It is FDA-approved for thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma
Grade	In-house
Polymorph	Form-C
GTI	Risk assessment report available
Nitrosamines	Risk assessment report available
DMF Availability	USDMF# 33083, ASMF # EU / ASMF / 00829
Manufacturing batch size	11.0 Kg
Production capacity	Annual capacity is 0.8-1.0 tonnes
Stability data	Available

Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*

Disclaimer:

The information provided on this webpage is based on the best available knowledge at the time of publication; however, accuracy and completeness are not guaranteed. Product specifications may change without notice. It is the responsibility of the purchaser or user to verify suitability and compliance. This product is intended for research use only and is not approved for human consumption.

Why Shilpa Pharma?

Happy Customers

Projects Successfully Completed

Established

PhD Experts Driving R&D Excellence

Team Size

World-Class API Manufacturing Sites

Global Audits Successfully Completed

Comprehensive CDMO Service Offerings

Our Lenvatinib Mesylate are also Available for

Questions & Answers

FAQ on Lenvatinib Mesylate

Everything You Need to Know About Shilpa Pharma

Shilpa Pharma – Your Trusted Global CDMO Partner

Delivering end-to-end solutions across API oncology, generics, peptides, polymers and specialty chemicals, we empower partners to accelerate development, ensure compliance, and reach markets faster with reliable, cost-effective innovation.